Close Menu

NEW YORK – Dutch biopharmaceutical company Byondis (formerly Synthon Biopharmaceuticals) said on Monday that Quantum Leap, the company sponsoring the ongoing Phase II/III I-SPY 2 trial for subgroups of women with breast cancer, has selected Byondis' antibody-drug conjugate SYD985 for inclusion in a new treatment arm of the study.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.